Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics
XLO Price/Volume Stats
| Current price | $0.70 | 52-week high | $1.70 |
| Prev. close | $0.68 | 52-week low | $0.62 |
| Day low | $0.67 | Volume | 891,000 |
| Day high | $0.74 | Avg. volume | 2,887,999 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 36.25M |
XLO Stock Price Chart Interactive Chart >
Xilio Therapeutics, Inc. (XLO) Company Bio
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
XLO Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XLO Price Returns
| 1-mo | -2.78% |
| 3-mo | -22.95% |
| 6-mo | -35.19% |
| 1-year | -33.33% |
| 3-year | -76.35% |
| 5-year | N/A |
| YTD | -26.70% |
| 2024 | 73.64% |
| 2023 | -79.55% |
| 2022 | -83.19% |
| 2021 | N/A |
| 2020 | N/A |